Johnson & Johnson Medical Korea in collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute invite innovators to submit robotic and surgical solutions Up to two winning robotics and surgical solutions will receive up to KRW 150,000,000 (~$134,000), entrance to the Seoul Bio Hub, one year of mentorship and coaching, and access to the JLABS global entrepreneurial community.
Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year. Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer. Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to flipping the script on lung cancer. How do we eliminate lung cancer by leveraging the totality of science and technology to prevent, intercept and cure lung cancer?